Evaluation__O and__O substantiation__O of__O health__O claims__O for__O EFSA__B-ORG on__O soy__O isoflavones__O and__O health:__O Health__O claims__O made__O in__O relation__O to__O food__O products__O require__O authorisation__O under__O EU__B-ORG law__O before__O they__O can__O be__O used__O in__O the__O labelling__O and__O marketing__O of__O products__O in__O the__O EU.__B-LOC
EFSA__B-ORG are__O the__O EU__B-ORG agency__O who__O are__O responsible__O for__O verifying__O the__O scientific__O substantiation__O of__O any__O health__O claims.__O
These__O health__O claims__O are__O a__O core__O marketing__O strategy__O that__O the__O global__O food__O industry__O employ__O to__O increase__O sales__O of__O premium__O products__O with__O claimed__O enhanced__O functionality.__O
For__O the__O consumer,__O the__O demonstration__O of__O evidence-__O based__O health__O claims__O can__O protect__O them__O from__O purchasing__O foods__O with__O misleading__O information__O on__O potential__O benefits.__O
To__O substantiate__O or__O refute__O the__O significant__O number__O of__O claims__O made__O by__O the__O food__O industry,__O EFSA__B-ORG (the__O EU__B-ORG agency__O that__O provides__O independent__O scientific__O advice__O and__O communication__O on__O existing__O and__O emerging__O risks__O associated__O with__O the__O food__O chain)__O committees__O comprehensively__O review__O all__O clinical__O trials__O and__O associated__O research__O following__O a__O submission__O by__O the__O food__O industry__O to__O produce__O a__O panel__O consensus__O document__O (EFSA__B-ORG scientific__O opinion).__O
Our__O research__O has__O been__O used__O to__O underpin__O a__O number__O of__O EFSA__B-ORG scientific__O opinions__O on__O health__O claims__O for__O isoflavones__O present__O in__O soy__O foods.__O
In__O 2009,__O the__O EFSA__B-ORG Panel__I-ORG on__O Dietetic__B-LOC Products,__I-LOC Nutrition__I-LOC and__O Allergies__B-LOC relied__O on__O some__O of__O our__O research__O (research__O reference__O 1-2)__O to__O develop__O a__O scientific__O opinion__O that__O cause__O and__O effect__O relationships__O have__O not__O been__O established__O between__O the__O consumption__O of__O soy__O isoflavones__O and__O the__O maintenance__O of__O bone__O mineral__O density__O in__O postmenopausal__O women.__O
Specifically,__O a__O distinct__O contribution__O of__O our__O work__O (research__O reference__O 2)__O was__O to__O draw__O attention__O to__O the__O `lack__O of__O evidence__O of__O a__O clear__O dose-response__O relationship__O between__O dietary__O intake__O of__O soy__O isoflavones__O and__O the__O claimed__O effect,__O and__O the__O different__O results__O obtained__O depending__O on__O the__O source__O and__O nature__O of__O the__O isoflavones__O used'__O (pp.6-7,__O corroborating__O source__O A).__O
This__O health__O claim__O was__O reviewed__O by__O EFSA__B-ORG in__O 2012,__O and__O our__O EU__B-ORG funded__O work__O (research__O reference__O 1)__O was__O used__O to__O further__O inform__O the__O opinion__O that__O consumption__O of__O soy__O isoflavones__O does__O not__O show__O an__O effect__O on__O bone__O mineral__O density__O (pp.__O
8&amp;12,__O corroborating__O source__O B).__O
As__O a__O result,__O the__O health__O claim__O was__O rejected__O by__O EFSA,__B-ORG and__O food__O companies__O (and__O others)__O are__O not__O permitted__O to__O promote__O food__O containing__O soy__O isoflavones__O for__O bone__O health__O in__O Europe.__B-LOC
Our__O research__O (research__O reference__O 2)__O was__O also__O key__O to__O the__O rejection__O of__O other__O soy__O health__O claims__O (corroborating__O source__O C)__B-ORG with__O the__O panel__O concluding__O that__O the__O evidence__O for__O a__O cause__O and__O effect__O relationship__O was__O not__O established__O between__O soy__O isoflavone__O consumption__O and__O a__O range__O of__O other__O health__O endpoints__O including__O vasomotor__O symptoms__O and__O cardiovascular__O risk__O factors.__O
Professor__B-PER Cassidy's__I-PER earlier__O work__O on__O soy__O foods,__O specifically__O soy__O protein,__O was__O used__O to__O underpin__O decisions__O on__O health__O claims__O relating__O to__O heart__O health__O in__O the__O USA__B-ORG (Food__I-ORG &amp;__I-ORG Drink__I-ORG Administration,__I-ORG 1999)__O and__O the__O UK__B-ORG Joint__I-ORG Health__I-ORG Claims__I-ORG Initiative__I-ORG (JHCI)__I-ORG (2002).__O
Risk__O assessment__O `Hazard__O characterisation__O of__O isoflavones'__O -__O Refinement__O of__O regulation__O EC__B-ORG 1924/2006:__O Professor__B-PER Cassidy,__I-PER through__O her__O research__O outputs__O and__O committee__O involvement__O has__O significantly__O informed__O the__O policy__O debate__O surrounding__O the__O potential__O risks:benefits__O of__O consuming__O soy__O isoflavones.__O
Some__O controversy__O surrounds__O the__O consumption__O of__O soy,__O given__O its__O oestrogenic__O potential__O and__O the__O potential__O for__O high__O levels__O of__O exposure__O in__O certain__O population__O groups__O through__O supplement__O use__O and__O soy__O infant__O formula.__O
Our__O research__O has__O influenced__O the__O consensus__O statements__O of__O international__O government__O agencies__O including__O EFSA,__B-ORG the__O American__B-ORG Heart__I-ORG Association__I-ORG (AHA)__I-ORG Advisory__I-ORG group__O and__O the__O UK__B-ORG Government__I-ORG Committee__I-ORG on__O Toxicity__B-ORG (COT),__I-ORG who__O have__O examined__O the__O potential__O hazards__O associated__O with__O consumption__O of__O soy__O isoflavones.__O
In__O the__O UK,__B-MISC COT's__O policy__O review__O of__O the__O toxicity__O of__O chemicals__O in__O the__O diet__O was__O informed__O by__O Cassidy's__O soy__O isoflavones__O based__O research.__O
The__O recent__O 2012__O initial__O report__O focusses__O on__O the__O infant__O diet__O in__O support__O of__O a__O review__O by__O the__O UK__B-ORG Government__I-ORG Scientific__I-ORG Advisory__I-ORG Committee__I-ORG on__O Nutrition__B-LOC on__O infant__O feeding.__O
In__O particular,__O the__O report__O uses__O UEA__B-ORG research__O (research__O reference__O 3)__O to__O provide__O scientific__O evidence__O on__O the__O absorption__O of__O isoflavones__O by__O the__O body,__O depending__O on__O age__O and__O the__O food__O source__O (pp.6-7,__O corroborating__O source__O G).__B-ORG
This__O expands__O on__O COT__O advice__O in__O 2003__O (corroborating__O source__O F),__B-ORG which__O used__O earlier__O Cassidy__O research,__O and__O partly__O defined__O the__O UK__B-LOC government's__O subsequent__O research__O programme__O on__O phytoestrogens/isoflavones.__O
Professor__B-PER Cassidy's__I-PER earlier__O work__O on__O soy__O also__O informed__O an__O American__B-ORG Heart__I-ORG Association__I-ORG advisory__O for__O health__O professionals__O on__O the__O risks:benefits__O from__O soy__O intake__O (2006,__O corroborating__O source__O H).__O
In__O summary,__O our__O impact__O has__O been__O to__O protect__O the__O public__O by__O providing__O balanced__O scientific__O evidence__O for__O health__O claims,__O and__O to__O raise__O awareness__O of__O the__O potential__O risk:benefit__O profile__O of__O consuming__O soy__O foods__O with__O a__O specific__O focus__O on__O isoflavones.__O
